Biotech Archives - Page 88 of 795

2 minute read

Amgen’s Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says

March 28, 2:28 PM

Raymond James resumes coverage of Amgen highlighting its diversified portfolio and strong presence across therapeutic areas for sustainable long-term growth. Innovative pipeline in oncology, rare diseases, and obesity offers promise, though uncertainties remain."

AMGN

2 minute read

4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease

By Vandana Singh

March 28, 2:04 PM

4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine for cystic fibrosis lung disease, including Phase 1/2 AEROW trial updates and Phase 3 clinical trial preparations.

FDMT

2 minute read

Johnson & Johnson Has An Opportunity In Talc-Cancer Lawsuit, Can Challenge Scientific Evidence In Federal Ruling

By Vandana Singh

March 28, 12:58 PM

Johnson & Johnson faces legal scrutiny over talc-cancer link. Recent rulings could impact 53,000+ lawsuits. Learn more about the $700 million settlement and evolving evidence in this ongoing litigation. J&J refutes claims, but legal battles continue.

JNJ

2 minute read

How Much Does It Cost To Make Novo Nordisk’s Ozempic? Shockingly Low Against $1,000 Price Tag, Study Shows

By Vandana Singh

March 28, 12:54 PM

Study reveals stark contrast: Novo Nordisk's Ozempic diabetes drug costs nearly $1,000 monthly in the U.S., yet could be produced for less than $5. This underscores the affordability challenge faced by patients amid soaring demand and insurers dropping coverage.

ELV

2 minute read

Extend Life Expectancy Against Aggressive Brain Cancers – Nano-Cap Firm Biodexa’s Investigational Drug Shows Potential

By Vandana Singh

March 28, 12:43 PM

Biodexa Pharmaceuticals' MTX110, revolutionizing brain cancer treatment with innovative drug delivery technology. Early trials show promising survival rate extensions in Diffuse Midline Glioma and Recurrent Glioblastoma patients. Learn more about MTX110's potential.

BDRX

2 minute read

Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session – Here’s Why

By Vandana Singh

March 28, 12:39 PM

Xilio Therapeutics soars with exclusive license pact with Gilead Sciences to advance XTX301, a Phase 1 tumor-activated IL-12 program. $43.5 million upfront, $604 million potential payments, and tiered royalties on global sales.

GILD

2 minute read

Insurance Coverage For Weight Loss Drugs – Elevance, CVS Health Become First To Extend Coverage To Novo Nordisk’s Successful Wegovy For Certain Patients

By Vandana Singh

March 28, 10:25 AM

Major U.S. health insurers CVS Health, Elevance Health, and Kaiser Permanente now reimburse for Novo Nordisk's Wegovy for specific Medicare individuals with heart-related conditions. This shift aims to alleviate financial burden and may prompt broader coverage, potentially impacting drug spending.

CVS

1 minute read

FDA Approves For Akebia Therapeutics’ Vafseo For Kidney Disease Associated Anemia

By Vandana Singh

March 28, 9:50 AM

The FDA-approved Vafseo tablets by Akebia Therapeutics for managing anemia in adult dialysis patients with chronic kidney disease. Learn about its once-daily oral HIF-PH inhibitor and global approval in 37 countries.

AKBA

2 minute read

Bio-Techne And Nikon Instruments Inc. Announce Partnership To Expand Access To Innovative Spatial Biology Services

By Benzinga Newsdesk

March 28, 9:09 AM

Bio-Techne Corporation (NASDAQ:TECH) is pleased to announce that Lunaphore, part of Bio-Techne's Spatial Biology Division, is partnering with Nikon Instruments Inc. (Nikon) to expand access to spatial biology

TECH

2 minute read

GeoVax To Present Data On GEO-CM04S1, A Next Generation Covid-19 Vaccine, At The World Vaccine Congress

By Benzinga Newsdesk

March 28, 9:06 AM

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present

GOVX